The relationship of nicotinamide adenine dinucleotide to the chondrogenic differentiation of limb mesenchymal cells.
The nicotinamide adenine dinucleotide (NAD) content of mesenchymal cells from the embryonic chick limb has been hypothesized to control the differentiation of these cells by modulation of ADP-ribosylations. To test this hypothesis, [35S]sulfate incorporation into proteoglycans was monitored as an estimate of the chondrogenic expression of cultured limb mesenchymal cells treated with nicotinamide and nicotinic acid to elevate cellular NAD levels or with nicotinamide and benzamide compounds to inhibit ADP-ribosylations. The results of this study indicated that serum component(s) modulate the interactions between these chemical agents and limb mesenchymal cells and, thus, complicate the interpretations of experiments performed in the presence of serum. With a chemically defined medium that promotes limb mesenchymal cell proliferation and differentiation in vitro, it was demonstrated that: (1) no clear correlation exists between cellular NAD content and the chondrogenic expression of cultured limb mesenchymal cells, (2) nicotinamide and benzamide compounds reduce cell proliferation and, at the higher doses tested, considerably reduce chondrogenesis in limb mesenchymal cell cultures, and (3) limb mesenchymal cells exhibit an enhanced susceptibility to benzamide compounds at a time very early in the culture period which temporally coincides with a transient increase in cellular ADP-ribosylation activity and initial chondrogenic differentiation. These results suggest that NAD does not control the differentiation of limb mesenchymal cells and that ADP-ribosylations are an integral, though not controlling, component of limb mesenchyme cytodifferentiation. A model is presented which proposes a role for ADP-ribosylations during the differentiation of limb mesenchymal cells.
Midura
R J
RJ
Cherney
B W
BW
Caplan
A I
AI
D000246:Adenosine Diphosphate Ribose / Q000378:metabolism; D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D002356:Cartilage / Q000196:embryology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002642:Chick Embryo; D005121:Extremities / Q000196:embryology*; D008648:Mesoderm / Q000166:cytology* / Q000378:metabolism; D009243:NAD / Q000378:metabolism*; D009525:Niacin / Q000494:pharmacology; D009536:Niacinamide / Q000494:pharmacology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011509:Proteoglycans / Q000096:biosynthesis; D013431:Sulfates / Q000378:metabolism
D001549:Benzamides; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011509:Proteoglycans; D013431:Sulfates; D009243:NAD; D000246:Adenosine Diphosphate Ribose; D009536:Niacinamide; D009525:Niacin